|
1
|
Rosen PP: Mucinous, Carcinoma Rosen's
Breast Pathology. 3rd. Lippincott and Wiliams & Wilkins;
Philadelphia: pp. 515–177. 2009
|
|
2
|
Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ
and Yang JH: Mucinous carcinoma of the breast in comparison with
invasive ductal carcinoma: Clinicopathologic characteristics and
prognosis. J Breast Cancer. 14:308–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Di Saverio S, Gutierrez J and Avisar E: A
retrospective review with long term follow up of 11,400 cases of
pure mucinous breast carcinoma. Breast Cancer Res Treat.
111:541–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diab SG, Clark GM, Osborne CK, Libby A,
Allred DC and Elledge RM: Tumor characteristics and clinical
outcome of tubular and mucinous breast carcinomas. J Clin Oncol.
17:1442–1448. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Komenaka IK, El-Tamer MB, Troxel A,
Hamele-Bena D, Joseph KA, Horowitz E, Ditkoff BA and Schnabel FR:
Pure mucinous carcinoma of the breast. Am J Surg. 187:528–532.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lacroix-Triki M, Suarez PH, MacKay A,
Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A
and Reis-Filho JS: Mucinous carcinoma of the breast is genomically
distinct from invasive ductal carcinomas of no special type. J
Pathol. 222:282–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan B, Yao R, Shi J, Xu QQ, Zhou YD, Mao
F, Lin Y, Guan JH, Wang XJ, Zhang YN, et al: Prognosis of subtypes
of the mucinous breast carcinoma in Chinese women: A
population-based study of 32-year experience (1983-2014).
Oncotarget. 7:38864–38875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paramo JC, Wilson C, Velarde D, Giraldo J,
Poppiti RJ and Mesko TW: Pure mucinous carcinoma of the breast: Is
axillary staging necessary? Ann Surg Oncol. 9:161–164. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang M, Teng XD, Guo XX, Zhao JS and Li
ZG: Clinicopathological characteristics and prognosis of mucinous
breast carcinoma. J Cancer Res Clin Oncol. 140:265–269. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanabe T, Sano M, Takashima S, Kitaya T,
Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K,
et al: Oral uracil and tegafur compared with classic
cyclophosphamide, methotrexate, fluorouracil as postoperative
chemotherapy in patients with node-negative, high-risk breast
cancer: National Surgical Adjuvant Study for Breast Cancer 01
Trial. J Clin Oncol. 27:1368–1374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anan K, Mitsuyama S, Tamae K, Nishihara K,
Iwashita T, Abe Y, Ihara T, Nakahara S, Katsumoto F and Toyoshima
S: Pathological features of mucinous carcinoma of the breast are
favourable for breast-conserving therapy. Eur J Surg Oncol.
27:459–463. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
National Comprehensive Cancer Network
Guidelines Version 1. 2015 Panel Members. https://www.nccn.orgAccessed. Aug 21–2017.
|
|
13
|
Gupta K, Sharma S, Kudva R and Kumar S:
Mixed mucinous and infiltrating carcinoma occurring in male breast-
study of clinico-pathological features: A rare case report. J Clin
Diagn Res. 9:ED07–ED08. 2015.PubMed/NCBI
|
|
14
|
Pawar PS, Poflee SV, Pande NP and
Shrikhande AV: Preoperative cytological diagnosis of mucinous
carcinoma (MC) of male breast. J Cytol. 33:58–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishida M, Umeda T, Kawai Y, Mori T, Kubota
Y, Abe H, Iwai M, Yoshida K, Kagotani A, Tani T and Okabe H:
Mucinous carcinoma occurring in the male breast. Oncol Lett.
7:378–380. 2014.PubMed/NCBI
|
|
16
|
Haid A, Kuehn T, Konstantiniuk P,
Köberle-Wührer R, Knauer M, Kreienberg R and Zimmermann G:
Shoulder-arm morbidity following axillary dissection and sentinel
node only biopsy for breast cancer. Eur J Surg Oncol. 28:705–710.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schrenk P, Rieger R, Shamiyeh A and Wayand
W: Morbidity following sentinel lymph node biopsy versus axillary
lymph node dissection for patients with breast carcinoma. Cancer.
88:608–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim M, Shin KH, Jung SY, Lee S, Kang HS,
Lee ES, Chung SH, Kim YJ, Kim TH and Cho KH: Identification of
prognostic risk factors for transient and persistent lymphedema
after multimodal treatment for breast cancer. Cancer Res Treat.
48:1330–1337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swaroop MN, Ferguson CM, Horick NK, Skolny
MN, Miller CL, Jammallo LS, Brunelle CL, O'Toole JA, Isakoff SJ,
Specht MC and Taghian AG: Impact of adjuvant taxane-based
chemotherapy on development of breast cancer-related lymphedema:
Results from a large prospective cohort. Breast Cancer Res Treat.
151:393–403. 2015.PubMed/NCBI
|
